Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | HEXA | P06865 | 1/20 | 0.42 |
| ▸ | HEXB | P07686 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807117 | 0.86 | CA12 (0.53) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL6197423 | 0.84 | CA12 (0.51) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL1034534 | 0.84 | CA12 (0.47) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL1764275 | 0.82 | CA12 (0.49) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL1037171 | 0.82 | CA12 (0.49) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL9111783 | 0.82 | CA12 (0.49) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL4532625 | 0.82 | CA12 (0.53) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL6198418 | 0.80 | ALDH1A1 (0.55) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL4101677 | 0.80 | CA12 (0.50) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL5659862 | 0.80 | CA12 (0.50) | CA12BRD4BRPF1CA9KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838696-B1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2016-03-09 | — | — | EP | disclosed |
| US-8053446-B2 | Cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2011-11-08 | — | — | US | disclosed |
| US-20080312275-A1 | Novel Cyanoguanidine Compounds | LEO PHARMA A/S (DK) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312275-A1 | Novel Cyanoguanidine Compounds | MKI67, CCNA1, COL1A1 | CA12 3904/4885BRD4 2563/4885BRPF1 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.